Why Does Tirzepatide / Semaglutide Make You Tired? GLP-1 Fatigue: Onset, Mechanism, and Management

Feeling tired after starting Wegovy, Zepbound, or Saxenda is not imaginary — it is a listed adverse reaction on every GLP-1 FDA label. The Wegovy prescribing information reports fatigue in 11% of treated patients versus 5% on placebo. Zepbound reports it in up to 7% at the 15 mg dose versus 3% placebo. Saxenda lists fatigue in 7.5% and asthenia (generalized weakness) in another 2.1%. This article explains why it happens, how long it lasts, and what you can safely do about it — all sourced from the verbatim FDA labels and the primary pivotal-trial publications.

TL;DR — Yes, fatigue is real, common, and usually temporary

GLP-1 fatigue is not a placebo effect or nocebo. It appears in randomized controlled trial adverse-event tables, at rates meaningfully above placebo, and is acknowledged on every FDA-approved GLP-1 prescribing label for weight management. At the same time, it is not universal — the majority of patients (roughly 89–93%) on the top doses of Wegovy and Zepbound do not report it as a formal adverse event. When it does occur, it is most intense during the first weeks of each dose escalation step and typically resolves within two to four weeks as the body adapts.

There are five distinct biological mechanisms driving fatigue in GLP-1 users, and most of them are modifiable. Understanding which mechanism is most likely causing your fatigue is the first step toward managing it safely.

• Caloric restriction energy gap — sharply reduced intake means fewer available calories for daily energy demands.
• GI side effects leading to dehydration — nausea and vomiting reduce both food and fluid intake simultaneously.
• Hypoglycemia — especially in type 2 diabetes patients on concurrent insulin or sulfonylurea; this is the medically urgent mechanism.
• Dehydration alone — blunted appetite also blunts thirst drive, causing under-hydration even without overt GI symptoms.
• B12 deficiency — a long-term risk, especially in patients also on metformin; produces fatigue, weakness, and neurological symptoms.

What FDA labels say about fatigue

The following verbatim quotes are from Section 6.1 (Adverse Reactions, Clinical Trials Experience) of each drug's current DailyMed prescribing information, verified 2026-05-10.

Wegovy (semaglutide 2.4 mg)

The Wegovy prescribing information Section 6.1 Table 3 (Adverse Reactions in Adult Patients with Overweight or Obesity) lists fatigue with the following footnote-annotated entry:

Fatigue^a — Placebo: 5% | WEGOVY 2.4 mg: 11%

Footnote a: “Includes fatigue and asthenia.”

Source: WEGOVY US Prescribing Information, Section 6.1, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Novo Nordisk Inc. Verified 2026-05-10.

The drug-attributable rate — the percentage of fatigue cases that can be attributed to the drug beyond placebo — is approximately 6 percentage points, or roughly 1 in 17 patients on the full 2.4 mg maintenance dose.

Zepbound (tirzepatide)

The Zepbound prescribing information Section 6.1 Table 1 (Adverse Reactions in Adult Patients with Obesity or Overweight — Studies 1 and 2) reports fatigue across the three dose levels tested in SURMOUNT-1:

Fatigue^e (Includes asthenia, fatigue, lethargy, malaise)

Placebo	ZEPBOUND 5 mg	ZEPBOUND 10 mg	ZEPBOUND 15 mg
3%	5%	6%	7%

Source: ZEPBOUND US Prescribing Information, Section 6.1, DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, Eli Lilly and Company. Verified 2026-05-10.

Fatigue incidence increases with dose — from 5% at 5 mg to 7% at 15 mg — suggesting a dose-response relationship. At the maximum 15 mg dose, the drug-attributable rate is approximately 4 percentage points above placebo.

Saxenda (liraglutide 3 mg)

The Saxenda prescribing information Section 6.1 Table 2 (Adverse Reactions in Adult Patients) lists two distinct fatigue-related entries:

Adverse Reaction	Placebo	SAXENDA 3 mg
Fatigue	4.6%	7.5%
Asthenia	0.8%	2.1%

Source: SAXENDA US Prescribing Information, Section 6.1, DailyMed SetID 3946d389-0926-4f77-a708-0acb8153b143, Novo Nordisk Inc. Verified 2026-05-10.

Mounjaro (tirzepatide for T2D)

The Mounjaro prescribing information Section 6.1 Table 1 (Adverse Reactions in Patients with Type 2 Diabetes Mellitus) does not list fatigue or asthenia as a standalone entry at the threshold incidence level reported in the weight-management trials. This is consistent with the pattern seen across GLP-1 labels: the weight-management trials (conducted in patients with obesity but without diabetes) tend to report fatigue at higher rates, likely because the caloric restriction effect is more pronounced when the drug is being used primarily to drive large weight loss rather than glycemic control. Patients using Mounjaro off-label or for T2D with concurrent weight management should still be counseled about fatigue as a class effect.

5 mechanisms behind GLP-1 fatigue

1. Caloric restriction energy gap

GLP-1 receptor agonists work, in part, by dramatically reducing appetite and food intake. In STEP-1, semaglutide patients reduced their daily caloric intake substantially — the degree of restriction is large enough to produce a temporary energy gap while the body adjusts its metabolic rate to match reduced intake. During this adjustment window (typically the first 4–8 weeks at each new dose), the body is running on fewer calories than it is accustomed to. This gap manifests as tiredness, lower exercise capacity, and a general feeling of low energy — entirely distinct from any drug effect on the nervous system.

This mechanism is self-limiting. As weight loss progresses and the body adapts its metabolic set point, most patients report their energy levels returning to baseline or improving, even while maintaining reduced caloric intake.

2. GI side effects leading to dehydration

Nausea is the most common adverse reaction across all GLP-1 weight management labels (15–44% at the highest doses). Vomiting affects roughly 5–24%. When patients are nauseated, they eat and drink less. When they vomit, they lose fluids and electrolytes they cannot easily replace. Dehydration — even mild dehydration of 1–2% body-water deficit — is a well-established cause of fatigue, reduced cognitive performance, and physical weakness.

This mechanism is most active during the first weeks of each dose escalation step. It can be meaningfully reduced by proactive hydration, eating smaller and more frequent meals, and avoiding high-fat or high-sugar foods that worsen GI motility.

3. Hypoglycemia (especially in T2D patients)

Hypoglycemia is the one fatigue mechanism that can escalate into a medical emergency. GLP-1 receptor agonists lower blood glucose. In patients with type 2 diabetes who are also on insulin or a sulfonylurea (glipizide, glimepiride, glyburide), the combined glucose-lowering effect can push blood glucose dangerously low. Low blood glucose produces profound fatigue, confusion, sweating, rapid heartbeat, and — if severe — loss of consciousness.

The specific FDA label hypoglycemia warnings are covered in detail in the hypoglycemia red flags section below.

4. Dehydration from blunted thirst drive

Separate from GI-induced dehydration, GLP-1 receptor agonists blunt appetite so effectively that many patients also drink less throughout the day. Hunger and thirst cues are partially co-regulated in the hypothalamus. When appetite signaling is suppressed, thirst signaling can be muted as well — leading patients to underhydrate without feeling classically thirsty. Over the course of a day, chronic mild dehydration accumulates and presents as persistent low-grade fatigue.

The management intervention here is explicit: set a daily water target (typically 8–10 cups or 2–2.5 L for adults) and track it actively, rather than drinking only when thirsty.

5. B12 deficiency (long-term users, especially on metformin)

Vitamin B12 deficiency is a long-term fatigue risk — not a titration-phase effect. GLP-1 receptor agonists reduce food intake broadly, including intake of B12-rich foods (meat, fish, dairy, eggs). Patients who are also on metformin face a compounded risk: metformin independently reduces B12 absorption at the ileal level by interfering with calcium-dependent absorption of the B12-intrinsic-factor complex.

B12 deficiency produces fatigue that is qualitatively different from titration fatigue — it is persistent, not dose-escalation-linked, and may be accompanied by tingling in the hands or feet (peripheral neuropathy), glossitis, or macrocytic anemia. Patients on long-term GLP-1 therapy, especially those concurrently on metformin, should discuss periodic B12 lab monitoring with their prescriber.

When fatigue onset typically occurs

GLP-1 fatigue follows a predictable pattern that correlates tightly with the dose-escalation schedule. Both Wegovy and Zepbound use a monthly titration ladder — patients start at a low dose and step up approximately every four weeks. Fatigue tends to onset within the first one to two weeks after each dose increase, as peak steady-state plasma drug levels rise and the acute appetite-suppressing effect intensifies.

The STEP-1 trial titration schedule for semaglutide (weekly 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, one dose per four weeks) means the highest-risk windows for fatigue onset are approximately:

• Weeks 1–5 (first dose): mild; most patients adapt quickly.
• Weeks 5–9 (first escalation to 0.5 mg): moderate risk; nausea rises in parallel.
• Weeks 9–13 (escalation to 1 mg): the 3rd step is often when fatigue is most reported.
• Weeks 13–17 (escalation to 1.7 mg): high-dose appetite suppression increases.
• Weeks 17–21+ (maintenance at 2.4 mg): most patients have adapted; fatigue in chronic form suggests another cause.

For Zepbound (tirzepatide), the SURMOUNT-1 titration runs from 2.5 mg to 5 mg to 10 mg to 15 mg on four-week intervals. The dose-response relationship in the fatigue data (3% placebo → 5% at 5 mg → 7% at 15 mg) confirms that higher doses carry proportionally higher risk.

How long fatigue lasts

Titration-phase fatigue is self-limiting for the majority of patients. Once the body adapts to a given dose level — typically within two to four weeks after an escalation step — energy levels return toward baseline. Patients who slow-titrate (remaining at each dose level for six to eight weeks rather than the standard four) often report lower peak fatigue intensity, though slow titration also extends the overall duration of the titration window.

Rule of thumb for duration:

• Weeks 1–2 post-escalation: fatigue most likely at its worst.
• Weeks 2–4 post-escalation: gradual improvement in most patients.
• Beyond 4 weeks at a stable dose: persistent fatigue is not expected and warrants investigation.
• Beyond 8 weeks at a stable dose: warrants prescriber evaluation to rule out hypoglycemia, dehydration, B12 deficiency, thyroid dysfunction, or anemia.

In clinical practice, patients sometimes experience the fatigue pattern resetting with each new dose escalation — feeling fine at 1 mg, then tired again for two weeks after moving to 1.7 mg. This is normal and expected. It does not mean the drug is not working or that fatigue will be permanent.

Hypoglycemia red flags

Hypoglycemia is the fatigue mechanism that can escalate into a medical emergency. The following are verbatim warnings from the FDA labels for each drug, verified 2026-05-10.

Wegovy — Section 5.4 verbatim

“WEGOVY lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia was increased when semaglutide injection or tablet was used concomitantly with insulin or an insulin secretagogue (e.g., sulfonylurea). When initiating WEGOVY, consider reducing the dose of concomitantly administered insulin or insulin secretagogue to reduce the risk of hypoglycemia.”

Source: WEGOVY US Prescribing Information, Section 5.4, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Novo Nordisk Inc. Verified 2026-05-10.

Zepbound — Section 5.7 verbatim

“ZEPBOUND lowers blood glucose and can cause hypoglycemia. Patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. In type 2 diabetes patients (Study 2), patients taking ZEPBOUND in combination with an insulin secretagogue had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%).”

Source: ZEPBOUND US Prescribing Information, Section 5.7, DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, Eli Lilly and Company. Verified 2026-05-10.

Saxenda — Section 5.4 verbatim

“Adult patients with type 2 diabetes mellitus on an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia with use of SAXENDA.”

Source: SAXENDA US Prescribing Information, Section 5.4, DailyMed SetID 3946d389-0926-4f77-a708-0acb8153b143, Novo Nordisk Inc. Verified 2026-05-10.

Mounjaro — Section 5.3 verbatim

“Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin may be necessary.”

Source: MOUNJARO US Prescribing Information, Section 5.3, DailyMed SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, Eli Lilly and Company. Verified 2026-05-10.

Practical point: If you are a type 2 diabetes patient on a GLP-1 AND a sulfonylurea or insulin, and you develop fatigue — especially fatigue accompanied by sweating, tremor, rapid heartbeat, or confusion — check your blood glucose immediately. Do not assume it is “just the GLP-1.” Hypoglycemia is treatable but can be dangerous if unrecognized. Your prescriber may need to reduce your sulfonylurea or insulin dose proactively when starting GLP-1 therapy.

B12 deficiency in long-term users

Vitamin B12 deficiency is a long-term concern — not a titration-phase risk. It develops slowly over months to years and is most relevant to patients who have been on a GLP-1 medication for six months or longer and who also:

• Take metformin (independent B12 depletion mechanism)
• Eat primarily or exclusively plant-based diets (low dietary B12)
• Are over 60 years of age (reduced gastric acid and intrinsic factor)
• Have prior gastric surgery or atrophic gastritis

The FDA labels for GLP-1 medications do not specifically warn about B12 deficiency as a GLP-1-specific risk — the concern is extrapolated from the long-term dietary restriction pattern these medications produce and the well-established drug interaction between metformin and B12 absorption.

Signs of B12 deficiency to watch for:

• Fatigue that is persistent and unrelated to dose changes
• Numbness or tingling in hands or feet (peripheral neuropathy)
• Glossitis (sore, smooth, inflamed tongue)
• Pale or jaundiced skin
• Mood changes or cognitive slowing

What to do: Ask your prescriber to include serum vitamin B12 in your next routine lab panel. Normal serum B12 is approximately 200–900 pg/mL; levels below 200 pg/mL are typically considered deficient, and many clinicians treat levels below 300 pg/mL in symptomatic patients. If deficient, supplemental B12 (oral or intramuscular depending on severity and cause) is safe to take alongside any GLP-1 medication. Over-the-counter cyanocobalamin or methylcobalamin supplements are available without a prescription, but discuss dosing with your prescriber or pharmacist before self-treating.

Management strategies

Most titration-phase GLP-1 fatigue can be significantly reduced with practical, non-pharmacologic strategies. These are consistent with guidance from the prescribing information's patient counseling sections and established clinical practice.

Slow titration

The FDA-approved titration schedules are minimums, not requirements. Both Wegovy and Zepbound labels describe the escalation as steps that “may” occur on the standard schedule — prescribers can hold patients at any dose level for additional weeks if tolerability is a concern. Patients who are experiencing significant fatigue or nausea at a given dose can ask their prescriber to extend the current dose period before the next escalation step. Slower titration reduces peak plasma level spikes and gives the body more time to adapt.

Active hydration

Do not wait until you are thirsty — on GLP-1 medications, the thirst signal is suppressed alongside the hunger signal. Set a daily water goal and track it. A practical target for most adults is 8–10 cups (2–2.5 liters) per day; higher if you are exercising or in a hot environment. Electrolyte-enhanced water or low-sugar electrolyte powders can help if you are experiencing active GI symptoms, since nausea and vomiting deplete sodium and potassium alongside fluid.

Protein at every meal

Protein has the highest satiety value per calorie and helps preserve lean muscle mass during rapid weight loss. It also stabilizes blood glucose more effectively than carbohydrate- or fat-dominant meals, reducing the risk of post-meal energy crashes. Aim for a protein source at every meal and snack — eggs, Greek yogurt, legumes, fish, poultry — even when appetite is minimal. A small high-protein snack is often better tolerated than a full meal during periods of GLP-1-induced nausea.

Electrolyte replacement

Sodium, potassium, and magnesium losses from GI side effects can directly produce fatigue and muscle weakness. If you are experiencing regular nausea or vomiting, consider:

• Adding a pinch of salt to water or using a low-sugar electrolyte drink
• Eating potassium-rich foods (banana, avocado, sweet potato) when tolerated
• Discussing magnesium supplementation with your prescriber if muscle cramps accompany fatigue

B12 if levels are low

If labs confirm B12 deficiency, supplementation is effective. Do not self-treat with high-dose B12 without a confirmed deficiency, but a standard multivitamin containing B12 is unlikely to cause harm and may prevent deficiency in long-term users. Discuss with your prescriber or pharmacist.

Sleep hygiene

Poor sleep amplifies perceived fatigue on GLP-1 medications. Common sleep disruptors during GLP-1 titration include nighttime nausea, late-evening GI discomfort, and — in T2D patients — nocturnal hypoglycemia. Practical adjustments:

• Inject Wegovy or Zepbound in the morning rather than at bedtime to shift the nausea peak away from sleep hours.
• Avoid large meals within 3 hours of sleep — gastroparesis-adjacent slowed emptying worsens when lying down.
• If you wake with sweating or anxiety, check blood glucose — this is the classical nocturnal hypoglycemia presentation.

When to call your prescriber

Call your prescriber (not just wait it out) if:

• Fatigue is severe enough to limit daily activities or work.
• Fatigue persists beyond 4 weeks at a stable dose.
• You are a T2D patient and fatigue is accompanied by any glucose dysregulation symptoms.
• You have not had B12 or thyroid labs in the past year.

When fatigue means STOP and call your prescriber

Mild-to-moderate fatigue during dose escalation does not, by itself, require stopping a GLP-1 medication. However, there are specific warning signs that require urgent medical attention. Stop your medication and seek care immediately if you experience fatigue with any of the following:

• Blood glucose below 70 mg/dL — or symptoms consistent with hypoglycemia (sweating, tremor, confusion, rapid heartbeat, vision changes) that do not resolve with oral glucose.
• Inability to keep fluids down for more than 24 hours — severe vomiting preventing oral hydration can rapidly progress to dehydration requiring IV fluids.
• Dark urine and markedly reduced urination — signs of significant dehydration or kidney stress.
• Severe generalized weakness — difficulty standing or walking that is out of proportion to typical tiredness.
• Fainting or near-fainting (syncope) — can indicate hypoglycemia, severe dehydration, or orthostatic hypotension.
• Chest pain, shortness of breath, or rapid irregular heartbeat — requires immediate evaluation regardless of GLP-1 status.
• Confusion, difficulty speaking, or sudden severe cognitive changes — can indicate severe hypoglycemia.

The Wegovy prescribing information reports one case of severe hypoglycemia (requiring assistance) in a weight-management trial patient — a WEGOVY-treated patient, none in placebo. This is a real, not theoretical, risk. Do not dismiss profound fatigue with neurological features in a GLP-1 user as “just the medication.”

Which GLP-1 causes the most fatigue? (cross-trial data)

Based on the FDA label adverse-reactions tables from their respective pivotal weight-management trials:

Frequently asked questions

Does tirzepatide make you tired?

Yes. The Zepbound (tirzepatide) FDA label Section 6.1 reports fatigue (including asthenia, lethargy, and malaise) in 7% of patients on the 15 mg dose versus 3% on placebo in SURMOUNT-1 weight reduction trials (PMID 35658024). Fatigue incidence is dose-dependent — 5% at 5 mg, 6% at 10 mg, 7% at 15 mg. It is most common during dose escalations and typically resolves within 2–4 weeks as the body adapts.

Does semaglutide make you tired?

Yes. The Wegovy (semaglutide 2.4 mg) FDA label Section 6.1 reports fatigue (including asthenia) in 11% of treated patients versus 5% on placebo in adult weight-reduction trials anchored to STEP-1 (PMID 33567185). The drug-attributable rate is approximately 6 percentage points above placebo. As with tirzepatide, semaglutide fatigue is most pronounced during the dose-escalation phase.

How long does GLP-1 fatigue last?

Titration-related fatigue typically peaks 1–2 weeks after a dose increase and resolves within 2–4 weeks as the body adapts. Fatigue persisting beyond 4 weeks at a stable dose is not expected and should be discussed with your prescriber. Persistent fatigue beyond 8 weeks warrants labs to check for hypoglycemia patterns, B12 deficiency, thyroid dysfunction, or anemia.

Should I stop my GLP-1 if I am tired?

Not automatically. Mild-to-moderate titration-phase fatigue is a known, listed, and usually self-limited adverse reaction. Do not stop without speaking to your prescriber. Call or seek urgent care immediately if fatigue is accompanied by confusion, rapid heartbeat, sweating, fainting, or blood glucose below 70 mg/dL — these suggest hypoglycemia or dehydration requiring urgent attention.

Can I take B12 with my GLP-1?

Yes. B12 supplementation is safe alongside any GLP-1 medication and is especially worth discussing with your prescriber if you are also on metformin or have been on a GLP-1 for more than six months. Ask your prescriber to check serum B12 at your next routine lab draw.

Why am I so tired on Wegovy?

The five most common causes in Wegovy users are: (1) caloric restriction energy gap — dramatically reduced intake creates a temporary shortfall; (2) GI-induced dehydration from nausea or vomiting; (3) dehydration alone from blunted thirst drive; (4) hypoglycemia — especially if you also use insulin or sulfonylurea; and (5) B12 deficiency in long-term users, particularly those also on metformin. The Wegovy FDA label reports fatigue in 11% of treated patients.

When should I worry about fatigue on a GLP-1?

Seek urgent care if fatigue is accompanied by: blood glucose below 70 mg/dL, confusion or difficulty concentrating, rapid heartbeat, profuse sweating, dizziness or fainting, inability to keep fluids down for more than 24 hours, or dark/reduced urine output. These symptoms indicate potentially serious hypoglycemia or dehydration. Fatigue alone, during dose escalation, without these signs, is almost always benign and self-limited — but always discuss any concerning symptom with your prescriber.

Related articles

• GLP-1 side-effect questions answered (Q&A hub) — complete coverage of every common GLP-1 side effect from the FDA labels and trial data.
• GLP-1 and mental health: anhedonia, emotional blunting, and the FDA's January 2026 suicidality reversal — a related side-effect deep-dive covering mood and neuropsychiatric evidence.
• Does tirzepatide / semaglutide cause depression? FDA postmarket surveillance + evidence review — the full arc of the historical suicidality warning, the FDA Drug Safety Communication (January 2026), clinical-trial PHQ-9 depression data, and warning signs to act on. Relevant when fatigue and low energy overlap with mood changes.
• GLP-1 shot beginner guide — injection technique, titration schedules, and first-month tips for new Wegovy and Zepbound users.
• Wegovy alternatives for weight management — if GLP-1 side effects including fatigue are intolerable, see our evidence review of alternative FDA-approved options.
• Why does tirzepatide cause diarrhea? Onset, mechanism, and management — the companion GI side-effect deep-dive: verbatim Zepbound and Mounjaro Section 5 kidney-injury warnings, dose-by-dose diarrhea rates from SURMOUNT-1, and SURPASS-2 head-to-head comparison with semaglutide.
• Why does tirzepatide cause headaches? Frequency, mechanism, and when to call your doctor — the companion side-effect deep-dive covering headache rates from the Zepbound FDA label (11–13% across doses vs 9% placebo), dehydration as the primary mechanism, acetaminophen vs NSAID safety, and emergency warning signs.
• Why am I not losing weight on compounded tirzepatide / semaglutide? (Plateau decision tree) — fatigue and low energy during a weight-loss plateau are closely related concerns. This companion article maps the five branches of GLP-1 non-response — from early titration through compound quality concerns — so patients can self-classify and know what to ask their prescriber.

Important disclaimer. This article is educational and does not constitute medical advice. The information above is a plain-language summary of FDA-approved prescribing information and published clinical trial data. Every clinical claim is sourced from the verbatim DailyMed FDA labels for the listed drugs or from PubMed-indexed primary-source publications cited in the References section. The choice of whether to start, stop, or modify a GLP-1 medication must be made with a licensed prescriber who knows your full medical history, comorbidities, medications, and individual risk factors. Do not self-treat hypoglycemia or dehydration symptoms — seek medical attention. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment.